

The Executive Office of Health & Human Services

Pharmacy and Therapeutics Committee Meeting Minutes



Tuesday, September 11, 2018

8:00 AM

HP Enterprise Services

301 Metro Center Blvd, Room 203

Warwick, Rhode Island 02886

P & T Members Present: Greg Allen, MD
Scott Campbell, RPh
Dave Feeney, RPh, Chairperson
Rita Marcoux RPh, Co-Chairperson
Matt Salisbury, MD
Rick Wagner, MD

Absent: Kristina Ward, PharmD

Others Present: Ann Bennett (DXC Technology)
Jerry Fingerut, MD (Conduent)
Karen Mariano, RPh (DXC Technology)
Kathryn Novak, RPh (Magellan Medicaid Administration)
Chris Ottiano, MD(NHP)

The meeting was called to order by the Chairperson once a quorum was in attendance - 8:08am.

Public Service Announcement by Magellan Medicaid Administration (MMA). CMS notified manufacturers regarding renewal of the federal rebate agreements, which need to be signed by end of the month. Further CMS asked MMA to communicate this information to their manufacturer contacts. Lack of signature will impact rebates to States, both the federal and supplemental rebates. Asking the pharmaceutical representatives in attendance today to share this information with their internal contacts.

The June 5th, 2018 meeting minutes were reviewed and by vote were accepted as presented.

Public testimony included the following speakers:

1. Vadim Ichaychuk, BMS, Orcenia.
2. Tysen Thompson, Embeda & Quillivant EP & XR.
3. Jonathan Hertz, Aerie, Rhopressa.
4. Tom Algozzine, Pfizer. Cosentyx.
5. William Seidel, Dynavel XR.

Magellan Medicaid Administration presented the following categories for the quarterly review:

1. Alzheimer's Agents. Namenda oral solution discontinued. Recommend no changes to the PDL. Motion was made to accept the recommendations; unanimously approved.
2. Analgesics, Narcotic Long Acting. FDA safety communication regarding the use of codeine and tramadol in children. ICER report on abuse deterrent formulations of opioids. AAOMS white paper on treatment of acute and post-op pain; recommending use of NSAIDS and non-opioid treatments. New product Arymo ER (MS ER). New generic for Butrans. Market withdrawal of Opana ER. No changes to the recommended products. Question; do other states have this as preferred and do they have same utilization rates? Motion was made to accept the recommendations; unanimously approved.

3. Analgesics, Narcotic Short Acting. New prod RoxyBand (oxycodone IR). Motion was made to accept the recommendations; unanimously approved.
4. Androgenic Agents. Discontinue Axiron and its generics. Question: Is there a diagnosis requirement on the PA; not currently. Referred for review by DUR. Motion was made to accept the recommendations; unanimously approved.
5. Antiparkinson's Agents. New items Gocovri (amantadine ER) and Osmolex ER (amantadine ER). Question: is there a reason for non-inclusion of the anticholinergics in this category? The category has changed over time based on the indications of amantadine not being used as an antiviral. Motion was made to accept the recommendations; unanimously approved.
6. Benign Prostatic Hyperplasia (BPH) Agents. No changes to the class. Motion was made to accept the recommendations; unanimously approved.
7. Bladder Relaxants. Updated indication for Myrbetriq. Changes to the recommendations: remove Enablex. Motion was made to accept the recommendations; unanimously approved.
8. Cytokine and Calmodulin (CaM) Antagonists. Updated indications for: Stelara, Taltz, Xeljanz and XR, Cimzia. New formulations: Cyltezo, Enbrel Mini and Kevzara. Two new Products: Ilumya (tildrakizumab-asmn) and Olumiant (baricitnib). Biosimilars should be considered safe and effective; substitutions should be made by the prescriber. No changes to the recommendations. Question: regarding superiority based on phase IV studies? Opinion a 16 week study would not be considered superiority study. Motion to accept the recommendations with the addition of Cosentyx. Motion: 2:3 in favor of motion with addition. Original motion passes: 3:2.
9. Erythropoietins. New information Biosimilar Retatrit (biosimilar for Epogen and Procrit. Mircera now approved for dialysis. Motion was made to accept the recommendations; approved with one abstention.
10. Ophthalmic Agents.
 - a. Allergic Conjunctivitis. Motion was made to accept the recommendations; unanimously approved.
 - b. Antibiotics. Motion was made to accept the recommendations; unanimously approved.
 - c. Antibiotic-steroid combinations. Motion was made to accept the recommendations; unanimously approved.
 - d. Anti-inflammatory. Recommendation includes elimination of prednisolone acetate. Motion was made to accept the recommendations; unanimously approved.
 - e. Anti-inflammatory, Immunomodulators. Motion was made to accept the recommendations; unanimously approved.
 - f. Glaucoma. Updated indication for Timoptic XE. New Prods Rhopressa (netarsudil mesylate) and Vyzulta (latanoprotene bunod). If there could be phase IV studies, then could be advantageous. Motion was made to accept the recommendations; unanimously approved.
11. Otic Agents.
 - a. Antibiotics. Motion was made to accept the recommendations; unanimously approved.
 - b. Anti-infectives and anesthetics. New category review for the committee. Low utilization at this point in time. Recommend acetic acid as the preferred product. Motion was made to accept the recommendations; unanimously approved.
 - c. Anti-inflammatory. New category for the committee. Recommend Dermotic. Motion was made to accept the recommendations; unanimously approved.
12. Phosphate Binders. New generic lanthanum carbonate chewable for fosrenol; new drug Axorerol. Motion was made to accept the recommendations; unanimously approved.
13. Stimulants & Related Agents. New formulations of Adzenys ER oral suspension. Product discontinuation Mehthylin chewable tablets. Recommendations include addition of Vynase chewable tablets and discontinuation of dextroamphetamine ER capsules. Comments; cCan the prior authorization be modified to ask if the patient has been on the medication? And from when? WHO has said that USA is an outlier in use of stimulants. Maintenance of chronic use and continuity of care. Motion was made to accept the recommendations; unanimously approved.
14. Antihypertensives, Sympatholytics. Motion was made to accept the recommendations; unanimously approved.

DUR – Follow up items:

1. DUR look at patient who need androgel and need dx based criteria.
2. Look at the use of stimulants in adults.

2018 Meeting Schedule:

December 11th

2019 Meeting Schedule:

April 9th

June 4th

September 10th

December 17th

Adjournment:

The meeting adjourned at 9:40 AM